SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders

References

• Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2006;95:644–650.
   Google Scholar
• Karp DD, Ervin TJ, Tuttle S, et al. Pulmonary complications during granulocyte transfusions: incidence and clinical features. Vox Sang. 1982;42(2):57–61.
   PubMed Web of Science ®Google Scholar
• O’Donghaile D, Childs RW, Leitman SF, et al. Blood consult: granulocyte transfusions to treat invasive aspergillosis in a patient with severe aplastic anemia awaiting mismatched hematopoietic progenitor cell transplantation. Blood. 2012;119:1353–1355.
   PubMed Web of Science ®Google Scholar
• Roilides E, Holmes A, Blake C, et al. Antifungal activity of elutriated human monocytes against Aspergillusfu-migatus hyphae: enhancement by granulocyte-macrophagec olony-stimulatingf actor and interferon-gamma. JInfect Dis. 1994;13(170):894–899.
   Google Scholar
• Roilides E, Sein T, Holmes A, et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillusfu migatus. J Infect Dis. 1995;172:1028–1034.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Böhme A, Cornely OA, et al. Prophylaxis of infectious complications with colony stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol. 2014;25:1709–1718.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Volpi I, Perruccio K, Tosti A. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype mismatched hematopoietic transplants. Blood. 2001;97:2514–2521.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340.
   PubMed Web of Science ®Google Scholar
• Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006;20:2087–2092.
   PubMed Web of Science ®Google Scholar
• Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009;27:3849–3854.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–1051.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Georgiadou SP, Wierda WG, et al. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1730–1733.
   PubMed Web of Science ®Google Scholar
• Itala M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol. 1996;57:46–53.
   PubMed Web of Science ®Google Scholar
• Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia. 1996;10:1509–1513.
   PubMed Web of Science ®Google Scholar
• Fianchi L, Leone G, Posteraro B, et al. Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. Leuk Res. 2012;36:331–333.
   PubMed Web of Science ®Google Scholar
• Fuhler GM, Drayer AL, Vellenga E. Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. Blood. 2003;101:1172–1180.
   PubMed Web of Science ®Google Scholar
• Fuhler GM, Knol GJ, Drayer AL, et al. Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol. 2005;77:257–266.
   PubMed Web of Science ®Google Scholar
• Ohsaka A, Saionji K, Igari J, et al. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol. 1997;98:108–113.
   PubMed Web of Science ®Google Scholar
• Elghetany MT, Peterson B, MacCallum J, et al. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res. 1997;21:801–806.
   PubMed Web of Science ®Google Scholar
• Shikama Y, Shichishima T, Ohto H, et al. Neutrophil-specific reduction in the expression of granulocyte–macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. Br J Haematol. 2000;111:863–872.
   PubMed Web of Science ®Google Scholar
• Wolach B, Gavrieli R, Manor Y, et al. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis. 1998;24:544–551.
   PubMed Web of Science ®Google Scholar
• Bendix-Hansen K. Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): incidence in untreated myeloproliferative disorders. Scand J Haematol. 1986;36:8–10.
   PubMedGoogle Scholar
• Rybka J, Butrym A, Wróbel T, et al. The expression of toll-like receptors in patients with B-cell chronic lymphocytic leukemia. Arch Immunol Ther Exp (Warsz). 2016;64(Suppl 1):147–150.
   PubMedGoogle Scholar
• Wei Y, Dimicoli S, Bueso-Ramos C, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27:1832–1840.
   PubMed Web of Science ®Google Scholar
• Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370:421–432.
   PubMed Web of Science ®Google Scholar
• Vekemans M, Robinson J, Georgala A, et al. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis. 2007;44:1593–1601.
   PubMed Web of Science ®Google Scholar
• Shaw BE, Confer DL, Hwang W, et al. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant. 2015;50:334–340.
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113:3604–3611.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81(7):1883–1888.
   PubMed Web of Science ®Google Scholar
• Hübel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002;42:1414–1421.
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Leonard K, Eiber G, et al. Alloimmunization after granulocyte transfusions. Transfusion. 1996;36:1009–1015.
   PubMed Web of Science ®Google Scholar
• Bashir S, Stanworth S, Massey E, et al. Neutrophil function is preserved in a pooled granulocyte component prepared from whole blood donations. Br J Haematol. 2008;140:701–711.
   PubMed Web of Science ®Google Scholar
• Hubel K, Rodger E, Gaviria JM, et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion. 2005;45:1876–1889.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Wirth K, Dwenger A, et al. Treatment and prophylaxis of severe infections in neutropenic patients by granulocytetransfusions. Ann Hematol. 2002;81:273–281.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Chinello P, De Silvestro G, et al. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer. 2003;11:101–106.
   PubMed Web of Science ®Google Scholar
• Rutella S, Pierelli L, Sica S, et al. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy. 2003;5:19–30.
   PubMed Web of Science ®Google Scholar
• Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004;101:2859–2865.
   PubMed Web of Science ®Google Scholar
• Grigull L, Pulver N, Goudeva L, et al. G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis. Support Care Cancer. 2006;14:910–916.
   PubMed Web of Science ®Google Scholar
• Kikuta A, Ohto H, Nemoto K, et al. Terapeutic transfusions of granulocytes collected by simple bag method for children with cancer and neutropenic infections: results of a single-centre pilot study. Vox Sang. 2006;91:70–76.
   PubMed Web of Science ®Google Scholar
• Ofran Y, Avivi I, Oliven A, et al. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang. 2007;93:363–369.
   PubMed Web of Science ®Google Scholar
• Drewniak A, Boelens JJ, Vrielink H, et al. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica. 2008;93:1058–1067.
   PubMed Web of Science ®Google Scholar
• Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica. 2009;94:1661–1668.
   PubMed Web of Science ®Google Scholar
• Al-Tanbal H, Al Humaidan H, Al-Nounou R, et al. The value and practicality of granulocyte transfusion: a single oncology centre experience. Transfus Med. 20:160–168.
   PubMed Web of Science ®Google Scholar
• Ang AL, Linn YC. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era–experience from an adult haematology unit in Singapore. Transfus Med. 2011;21:13–24.
   PubMed Web of Science ®Google Scholar
• Atay D, Ozturk G, Akcay A, et al. Effect and safety of granulocyte transfusions in pediatric patients with febrile neutropenia or defective granulocyte functions. J Pediatr Hematol Oncol. 2011;33:220–225.
   Web of Science ®Google Scholar
• Kim KH, Lim HJ, Kim JS, et al. Therapeutic granulocyte transfusions for the treatment of febrile neutropenia in patients with hematologic diseases: a 10-year experience at a single institute. Cytotherapy. 2011;13:490–498.
   PubMed Web of Science ®Google Scholar
• Cherif H, Axdorph U, Kalin M, et al. Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. Scand J Infect Dis. 2013;45:112–116.
   PubMed Web of Science ®Google Scholar
• Raad II, Chaftari AM, Al Shuaibi MM, et al. Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications. Ann Oncol. 2013;24:1873–1879.
   PubMed Web of Science ®Google Scholar
• Díaz R, Soundar E, Hartman SK, et al. Granulocyte transfusions for children with infection and neutropenia or granulocyte dysfunction. Pediatr Hematol Oncol. 2014;31:425–434.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez G, Zuniga J, et al. Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions. Acta Haematol. 2014;131:50–58.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Remy KE, Strich JR, et al. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015;55:2076–2085.
   PubMed Web of Science ®Google Scholar
• Nikolajeva O, Mijovic A, Hess D, et al. Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience. Bone Marrow Transplant. 2015;50:846–849.
   PubMed Web of Science ®Google Scholar
• Teofili L, Valentini CG, Di Blasi R, et al. Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia. PLoS One. 2016;11:e0159569.
   PubMed Web of Science ®Google Scholar
• Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997;11:1621–1630.
   PubMed Web of Science ®Google Scholar
• Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol. 1999;106:689–696.
   PubMed Web of Science ®Google Scholar
• Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–3309.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Chung IJ, Park MR, et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia. 2001;15:203–207.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Song HC, Chung IJ, et al. Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections. Haematologica. 2004;89:632–633.
   PubMed Web of Science ®Google Scholar
• Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84:734–741.
   PubMed Web of Science ®Google Scholar
• Sachs UJ, Reiter A, Walter T, et al. Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections. Transfusion. 2006;46:1909–1914.
   PubMed Web of Science ®Google Scholar
• Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008;42:679–684.
   PubMed Web of Science ®Google Scholar
• Seidel MG, Minkov M, Witt V, et al. Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol. 2009;31:166–172.
   PubMed Web of Science ®Google Scholar
• Heim KF, Fleisher TA, Stroncek DF, et al. The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion. 2011;51:1154–1162.
   PubMed Web of Science ®Google Scholar
• Massey E, Harding K, Kahan BC, et al. The granulocytes in neutropenia 1 (GIN 1) study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma. Transfus Med. 2012;22:277–284.
   PubMed Web of Science ®Google Scholar
• Oztürkmen S, Altuntaş F, Olcay L. Granulocyte transfusion therapy in paediatric patients with severe neutropenic infection. Transfus Apher Sci. 2013;48:381–385.
   PubMed Web of Science ®Google Scholar
• Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126:2153–2161.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Stanworth SJ, Hopewell S, et al. Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2016;4:CD005339.
   PubMedGoogle Scholar
• Deutsches Register Klinischer Studien. DRKS00000218. Tansfusion of granulocytes for patients with febrile neutropenia (GRANITE) Registration; 2011 May 4 [cited March 31, 2017]. Available from: www.drks.de/DRKS00000218
   Google Scholar
• Guide to the preparation, use and quality assurance of blood components. 18th ed. Strasbourg, France: European Directorate for the Quality of Medicines & HealthCare (EDQM); 2015.
   Google Scholar
• Standards for Blood Banks and Transfusion Services. 30th ed. Bethesda, MD: American Association of Blood Banks (AABB); 2016.
   Google Scholar
• Ozer H, Armitage JO, Bennett CL, et al. update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18::3558-85.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheresian J, Lyman GH, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:1–19.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. National comprehensive cancer network clinical practice guidelines in oncology: myeloid growth factors version 1. 2012. Available from: http://www.nccn.org
   Google Scholar
• Rao R, Shammo JM, Enschede SH, et al. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma. Clin Lymphoma. 2005;6:26–30.
   PubMedGoogle Scholar
• Lehrnbecher T, Zimmermann M, Reinhardt D, et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109:936–943.
   PubMed Web of Science ®Google Scholar
• Inaba H, Cao X, Pounds S, et al. Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. Cancer. 2011;117:1313–1320.
   PubMed Web of Science ®Google Scholar
• Hallböök H, Björkholm M, Hägglund H, et al. Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma. 2009;50:1872–1874.
   PubMed Web of Science ®Google Scholar
• Yakushijin Y, Shikata H, Takaoka I, et al. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy. In J Clin Oncol. 2011;16:118–124.
   Web of Science ®Google Scholar
• Ozkan HA, Ozer UG, Bal C, et al. Daily vs every other day administration of G-CSF following autologous peripheral stem cell transplantation: a prospective randomized study. Transf Apher Sci. 2013;49:163–167.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27–34.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Goldstone AH, Littlewood T, et al. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol. 2009;146:54–63.
   PubMed Web of Science ®Google Scholar
• Hertzberg M, Matthews JP, Stone JM, et al. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. Am J Hematol. 2014;89:536–541.
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Watanabe T, Gosho M, et al. Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study. Leuk Lymphoma. 2016;57:1657–1664.
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Krailo M, Chen Z, et al. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2005;45:274–280.
   PubMed Web of Science ®Google Scholar
• Sebban C, Lefranc A, Perrier L. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer. 2012;48:713–720.
   PubMed Web of Science ®Google Scholar
• Sierra J, Szer J, Kassis J, et al. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer. 2008;8:195–199.
   PubMed Web of Science ®Google Scholar
• Rifkin R, Spitzer G, Orloff G, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:186–191.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Nesi F, Tridello G, et al. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PLoS One. 2013;8:e53252.
   PubMed Web of Science ®Google Scholar
• Martino M, Praticò G, Messina G, et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol. 2006;77:410–415.
   PubMed Web of Science ®Google Scholar
• Kubo K, Miyazaki Y, Murayama T, et al. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol. 2016;174:563–570.
   PubMed Web of Science ®Google Scholar
• Engert A, Griskevicius L, Zyuzgin Y, et al. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009;50:374–379.
   PubMed Web of Science ®Google Scholar
• Publicover A, Richardson DS, Davies A, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol. 2013;162:107–111.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Cerchiara E, Dessanti ML, et al. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. Br J Haematol. 2015;169:293–296.
   PubMed Web of Science ®Google Scholar
• Uddin S, Russell P, Farrell M, et al. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant. Ther Adv Hematol. 2015;6:53–60.
   PubMed Web of Science ®Google Scholar
• Pham T, Patil S, Fleming S, et al. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. Transfusion. 2015;55:2709–2713.
   PubMed Web of Science ®Google Scholar
• Cesaro S, Tridello G, Prete A, et al. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. Transfusion. 2015;55:246–252.
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Clark OAC, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia (Review). Cochrane Database Syst Rev. 2016;10:1–77.
   Google Scholar
• Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012;6:1–3.
   Google Scholar
• Thomas J, Smith TJ, Bohlke K, et al. Recommendations for the use of WBC growth factors: American Society Of Clinical Oncology clinical practice guideline update. Jco. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase 111 study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–462.
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671–1677.
   PubMed Web of Science ®Google Scholar
• Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial bythe European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Jco. 1996;14:2150–2159.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. Jco. 1997;15:3496–3506.
   PubMed Web of Science ®Google Scholar
• Witz F, Sadoun A, Perrin MC, et al. Placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood. 1998;91:2722–2730.
   PubMed Web of Science ®Google Scholar
• Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116:177–178.
   PubMed Web of Science ®Google Scholar
• Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase i11 study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood. 1993;82:2329–2339.
   PubMed Web of Science ®Google Scholar
• Yau NC, Neidhart JA, Trioui P, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol. 1996;51:289–295.
   PubMed Web of Science ®Google Scholar
• Wan L, Zhang Y, Lai Y, et al. Effect of granulocyte-macrophage colonystimulatingfactor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized Phase IV trial. Jco. 2015;33:3999–4405.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–60.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–19.
   PubMed Web of Science ®Google Scholar
• Platzbecker U. Randomized, placebo-controlled, Phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myeloid leukemia — a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013;122:5214; Abstract 5214 ASH 2013.
   Web of Science ®Google Scholar
• Frey N. Oral thromboietin receptor agonist eltrombopag treatment during induction chemotherapy for acute myelogenous leukemia (AML): results of a randomized, double blind, phase 2 study. Haematologica 2016;101:1-881 (abstract P185).
   Google Scholar
• Nairz M, Sonnweber T, Schroll A, et al. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 2012;14:238–246.
   PubMed Web of Science ®Google Scholar
• Jaspers A, Baron F, Maertens J, et al. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am J Hematol. 2015;90:E133–4.
   PubMed Web of Science ®Google Scholar
• JaspersA, BaronF, ServaisS. Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. Am J Hematol. 2015;90:E197–9.
   PubMed Web of Science ®Google Scholar